JORDAN, Allan,NEWTON, Rebecca,WASZKOWYCZ, Bohdan,SUTTON, Jonathan Mark,HYND, George,PAOLETTA, Silvia,FORDYCE, Euan Alexander Fraser
申请号：
AU2020220079
公开号：
AU2020220079A1
申请日:
2020.08.18
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020220079A120200903.pdf#####ABSTRACT The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: X2 R3 b C x3 X4 d R2 HET Formula I wherein HET, bonds a, b, c and d, X 1 , X 2 , X3 , X4 , R 2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
